Abstract
This clinical trials review is derived from the presentations made at the Third International Conference on Bipolar Disorder, held June 17-19, 1999 in Pittsburgh, PA, published as abstracts in Bipolar Disorders: An International Journal of Psychiatry and Neurosciences, Edited by Jair C. Soares, and Samuel Gershon. In this review, abstracts reporting on the efficacy of "third generation" anti-epileptic agents, including topiramate, lamotrigine, diphenylhydantoin, gabapentin, and the new generation antipsychotic agent, olanzapine in treating bipolar disorders are reviewed.
MeSH terms
-
Acetates / pharmacology
-
Acetates / therapeutic use
-
Amines*
-
Anticonvulsants / pharmacology
-
Anticonvulsants / therapeutic use
-
Antimanic Agents / pharmacology
-
Antimanic Agents / therapeutic use
-
Benzodiazepines
-
Bipolar Disorder / drug therapy*
-
Bipolar Disorder / psychology
-
Clinical Trials as Topic
-
Cyclohexanecarboxylic Acids*
-
Fructose / analogs & derivatives
-
Fructose / pharmacology
-
Fructose / therapeutic use
-
Gabapentin
-
Humans
-
Lamotrigine
-
Olanzapine
-
Phenytoin / pharmacology
-
Phenytoin / therapeutic use
-
Pirenzepine / analogs & derivatives*
-
Pirenzepine / pharmacology
-
Pirenzepine / therapeutic use
-
Topiramate
-
Treatment Outcome
-
Triazines / pharmacology
-
Triazines / therapeutic use
-
gamma-Aminobutyric Acid*
Substances
-
Acetates
-
Amines
-
Anticonvulsants
-
Antimanic Agents
-
Cyclohexanecarboxylic Acids
-
Triazines
-
Topiramate
-
Benzodiazepines
-
Fructose
-
Pirenzepine
-
gamma-Aminobutyric Acid
-
Phenytoin
-
Gabapentin
-
Olanzapine
-
Lamotrigine